ReviewWorld journal of gastroenterology2005
Loss of heterozygosity analyzed by single nucleotide polymorphism array in cancer.
Review in World journal of gastroenterology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- A pan-cancer analysis of ABI3BP: a potential biomarker for prognosis and immunoinfiltration.Frontiers in oncology · 2023Article
- Diagnostic molecular techniques in haematology: recent advances.Annals of translational medicine · 2018Review
- SNPs Array Karyotyping in Non-Hodgkin Lymphoma.Microarrays (Basel, Switzerland) · 2015Review
- Molecular diagnostics: techniques and recommendations for 1p/19q assessment.CNS oncology · 2015Review
- Application of SNP microarrays to the genome-wide analysis of chromosomal instability in premalignant airway lesions.Cancer prevention research (Philadelphia, Pa.) · 2014Article
- Sputum-based molecular biomarkers for the early detection of lung cancer: limitations and promise.Cancers · 2011Article
- High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity.Nature biotechnology · 2010Article
- Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array.Neoplasia (New York, N.Y.) · 2008Article
- High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping.Genome research · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoplastic progression is generally characterized by the accumulation of multiple genetic alterations including loss of tumor suppression gene function. Loss of heterozygosity (LOH) has been used to identify genomic regions that harbor tumor suppressor genes and to characterize different tumor types, pathological stages and progression. LOH pattern has been detected by allelotyping using restriction fragment length polymorphism, and later by simple sequence length polymorphisms (SSLPs or microsatellite) for 10 years. This paper reviews the detection of LOH by recently developed single nucleotide polymorphism (SNP) arrays (all analyzed by Affymetrix array); furthermore, its advantage and disadvantage were analyzed in several kinds of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.